Background-TNF/TNFR superfamily members conform a group of molecular interaction pathways of essential relevance during the process of T cell activation and differentiation towards effector cells and particularly for the maintenance phase of the immune response. Specific blockade of these interacting pathways, such as CD40/CD40L, contributes to modulate the deleterious outcome of allogeneic immune responses. We postulated that antagonizing the interaction of LIGHT expression on activated T cells with its receptors, HVEM and LTβR may decrease T cell-mediated allogeneic responses.
Introduction
Human LIGHT (homologous to lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes) is a member of the TNF superfamily transiently detected on human T cells upon activation (1, 2) and immature dendritic cells (3, 4) . Mouse LIGHT is a type II transmembrane protein of 239 amino acids, with an extracellular region 74% similar in amino acid sequence to human LIGHT (1, 5) .
LIGHT can act as a costimulatory molecule independently of CD28 (3, 4) , fostering T cell proliferation in the mixed lymphocyte reaction and promoting the process of DC maturation as well (6) . It can even augment antitumor activity directly (7) or indirectly through enhancing CTL activity against tumor cells (4) . In line with the costimulatory activity of LIGHT, constitutive transgenic expression of LIGHT under the control of a T cell-specific promoter led to chronic inflammation of mucosal tissues (8, 9) . In contrast, gene deletion of LIGHT results in defective CD8 T cell proliferation and acquisition of CTL effector function, which is associated with prolonged graft survival in several allogeneic mouse models of transplantation (10) (11) (12) (13) .
One of the LIGHT receptors is HVEM (TNFRSF14), which is broadly expressed on hematopoietic and non hematopoietic cells (14, 15) . HVEM is a type I transmembrane molecule with an extracellular portion divided into cysteine-rich domains (CRD1-4) (16) (17) (18) with distinct binding sites for its ligands. BTLA and CD160 bind to the CRD1 and part of the CRD2 of HVEM, and so does the viral protein gD of Herpes Simplex Virus (HSV) (19, 20) , whereas LIGHT interacts with CRD2 and CRD3 on opposite sides of the extracellular part of HVEM (21) . Furthermore, membrane LIGHT can be released by the action of a metalloprotease (22) and the soluble form of LIGHT binds to BTLA/HVEM complex and strengthens the molecular interaction, whereas engagement of membrane anchored HVEM by LIGHT in cis displaces BTLA from its interaction with HVEM and allows bidirectional trans co-stimulatory contacts between HVEM and LIGHT (1, 23, 24) .
The other well-characterized receptor of LIGHT is the LTβR, which is expressed on follicular dendritic cells (FDCs), dendritic cells (DCs), macrophages, stromal cells and high endothelial venules (HEV) (25) . LTαβ CD4 + CD3 − inducer cells interact with LTβR on stromal organizer cells to guide lymphoid organogenesis during development and, later on, stroma-derived LTβR signaling is still essential for the maintenance of the lymphoid tissue structure (26, 27) . LTαβ expression on activated CD4 + helper T cells (28) and LTβR on DCs and B cells follows a similar pattern to that of CD40L and CD40 expression on T cells and antigen presenting cells respectively, suggesting that LTαβ/LTβR pathway may regulate the exchange of information between antigen presenting cells and T cells, and therefore participate in T cell activation and differentiation. LIGHT expressed on activated T cells may provide a licensing signal upon interaction with LTβR expressed on DC (6) or on stromal cells that would in turn modify the lymphoid tissue environment to achieve proper T cell priming.
So far, there have been no reagents available capable to specifically recognize conformational epitopes on the extracellular region of the mouse LIGHT, although reagents against human LIGHT are available (6), (29) . In an attempt to define the therapeutic potential of targeting LIGHT in animal model systems, and to detect and follow membrane LIGHT expression, rat monoclonal antibodies against mouse LIGHT were raised and selected based on their ability to block the binding of soluble LTβR-Ig or HVEM-Ig to LIGHT-transduced cells. Their therapeutic activity was then assessed in an in vivo mouse model of alloreactivity and we demonstrated that the specific blockade of LIGHT mitigated the in vivo cytotoxic allogeneic immune response. These observations pointed out that LIGHT/HVEM/LTβR interacting pathway is an amenable therapeutic target for the immune intervention for the control of cell-mediated cytotoxic responses.
Results

Conserved cross-interactions between mouse LIGHT receptors and mouse and human LIGHT
The TNF receptor-binding domain of LIGHT interacts with CRD2 and CRD3 on one side of membrane anchored HVEM, whereas BTLA and CD160 interact with CRD1 and CRD2 on the opposite side of HVEM (2, 21, 30) . According to molecular modeling and previous studies, the receptors HVEM, LTβR and DcR3 share widely overlapping binding sites on LIGHT (2). DcR3 is a soluble decoy receptor that is present in human but has no known counterpart in mouse. Interactions of mouse LIGHT with its receptors are not very well documented, in part due to the difficulty of preparing active soluble mouse LIGHT (31) . We indeed found that either recombinant soluble mouse LIGHT fused to an IgG 2a Fc fragment, or LIGHT multimerized with an isoleucine zipper, failed to bind its receptors (data not shown) (32) . However, a third soluble form of mouse LIGHT, containing amino acids 72-239 linked to a Flag-Foldon tag proved to be active and efficiently reacted with mouse HVEM, mouse LTβR and human DcR3 expressed as full-length or glycolipid-anchored proteins on HEK-293T cells ( Figure 1A ). Human LIGHT gave a similar binding pattern, except that its binding to mouse LTβR was weaker in this particular experimental setting ( Figure 1A ). Similar results were obtained when cells expressing full-length mouse or del Rio et al. human LIGHT were stained with receptor.Ig fusion proteins. In these experiments, mouse HVEM and mouse LTβR bound to mouse and human LIGHT, whereas human DcR3 gave weaker stainings ( Figure 1B ).
Taken together, the binding results indicate that in the mouse system, LIGHT indeed binds the relevant receptors HVEM and LTβR, which is in agreement with and extends conclusions of previous reports describing the binding interactions between LIGHT and its natural receptors (7, 31) .
Differential competition of soluble forms of LTβR and HVEM for binding to LIGHT
HVEM delivers costimulatory signals to T cells when engaged by LIGHT, while LIGHT/ LTβR functionally modulates dendritic cells and stromal cells to promote an adequate environment for T cell priming (33, 34) . Since both LTβR and HVEM bind to LIGHT, when both receptors are simultaneously expressed in cis (on the same cell) or in trans (in different cells), the advantageous competition of one of the receptors over the other would displace the less competitive receptor from interacting with LIGHT (2) . Under those circumstances, binding of the receptor with the highest affinity may dominate a particular signaling pathway. Saturation LIGHT binding curves were established for mHVEM.IgG 2a (HVEMIg) and for mLTβR.IgG 1 (LTβR-Ig). Interestingly, concentrations of receptors required to achieve saturation binding was about 20-fold higher for HVEM-Ig than for LTβR-Ig ( Figure  2A These experiments suggest that HVEM, at least in its recombinant form, has a lower affinity for mouse LIGHT than for mouse LTβR and confirm that HVEM and LTβR binding sites on LIGHT overlap.
Anti-LIGHT antibodies that efficiently recognize and block mouse LIGHT
A LIGHT-transduced NIH-3T3 cell line coexpressing eGFP (clone 2B7) was obtained by limiting dilution cloning and used as immunogen in rats to produce anti-mouse LIGHT hybridomas. Hybridoma supernatants were screened for their recognition of mouse LIGHT by flow cytometry using LIGHT-GFP-or control GFP-transduced NIH-3T3 cell lines. Four rat IgG 2a anti-LIGHT antibodies (10F12, 3G1, 6H12 and 9B7) specifically recognized an epitope located at the extracellular region of mouse LIGHT ( Figure 3A , left panels). Of note, all four antibodies cross-reacted with human LIGHT expressed on transiently transfected HEK-293T cells ( Figure 3A , right panels).
Anti-LIGHT antibodies were screened for their ability to prevent the binding of HVEM-Ig and LTβR-Ig to LIGHT-transduced cells. Two anti-LIGHT antibodies (10F12 and 3G1) fully prevented the binding of HVEM-Ig to mouse LIGHT-expressing cells in a FACSbased assay, whereas antibodies 9B7 and 6H12 did not ( Figure 3B ). Anti-LIGHT, clone 10F12 was the most potent antibody to inhibit the binding of LTβR-Ig to mouse LIGHT, del Rio et al.
although inhibition did not reach baseline, whereas 3G1 only partially inhibited this interaction ( Figure 3B ).
Anti-LIGHT mAb 10F12 was further characterized in a binding assay between membranebound and soluble LIGHT, in which 10F12 binding to membrane-bound LIGHT is competed by soluble Flag-Foldon (FF)-LIGHT ( Figure 3C ). At the EC 50 , 10F12 and FF-LIGHT were at equimolar concentrations, indicating no obvious bias of 10F12 to recognize membrane-bound LIGHT, and therefore validating the quality of soluble recombinant FF-LIGHT. The ability of 10F12 to prevent the binding of FF-LIGHT to membrane-bound HVEM and LTβR was then investigated (Figures 3D, E) . 10F12 inhibited the binding of FF-LIGHT to both full-length HVEM and GPI-anchored LTβR with a similarly good efficiency: at EC 50 , the ratio of antibody binding sites to FF-LIGHT epitopes was stoichiometric, and a five-fold molar excess of antibody to LIGHT totally abrogated LIGHT binding to both receptors ( Figures 3D, E) . Of the nineteen mouse TNF family members, 10F12 only recognized LIGHT in a sandwich ELISA assay, validating its binding specificity ( Figure  3F ). The affinity of the interaction of FF-LIGHT with a monomeric Fab fragment of 10F12 prepared by ficin digestion ( In summary, we have identified both blocking and non-blocking monoclonal antibodies recognizing surface-exposed mouse LIGHT that cross-reacted with human LIGHT. One of these antibodies had decent binding parameters and showed efficient and specific blockade of the interaction of LIGHT with its two receptors, making it possible for the first time to monitor the expression of mouse LIGHT at protein level and to conduct LIGHT-blocking therapeutic experiments in mice.
Mouse LIGHT is transiently expressed on activated CD8 T cells and NK cells, and to a lesser extent in CD4 T cells
Anti-LIGHT antibodies were tested for their ability to detect endogenous LIGHT. Considering that in humans, LIGHT protein is not detectable on resting T cells, fresh mouse B6 WT and B6 LIGHT KO splenocytes were stimulated in vitro with PMA plus ionomycin for 5 h in the presence of either HiLyte-647 labeled anti-LIGHT (10F12) or HiLyte-647-labeled rat IgG 2a isotype control. This strong polyclonal T cell activation prompted a transient expression of LIGHT that was readily detected in virtually all CD8 T cells and to a lower extent in a subset of CD4 T cells of WT B6 mice, but not in LIGHT-deficient T cells ( Figure 4A ), in line with the previous description of LIGHT expression in human T cells (29) , (1) . Polyclonal activation with PMA plus ionomycin also induced transient expression of LIGHT on NK cells, but not in similarly stimulated LIGHT KO NK1.1 cells ( Figure 4B) . Because of the transient expression of LIGHT in activated T cells, it is noteworthy to mention that the labeled antibody needs to be present during the course of activation in order to achieve successful detection. 
In vivo allogeneic cytotoxic activity is significantly reduced after antibody-mediated blockade of the LIGHT/HVEM/LTβR pathway, although to a lesser extent than in LIGHTdeficient mice
To elucidate whether antibody blockade of the LIGHT/HVEM/LTβR pathway could modulate allogeneic cytotoxic responses, B6 recipient mice were injected with an identical number of B6, BALB/c and F1 target cells labeled with different amounts of CFSE, as mentioned in the Material and Methods section. As shown in figure 5 , the percentage of killing of allogeneic BALB/c and F1 target cells in host B6 spleen ( Figure 5A ) and peripheral lymph nodes ( Figure 5B ) was significantly reduced in LIGHT-deficient mice compared to B6 WT mice (BALB/c target cells: spleen and pLNs, p<0.0005 and F1 target cells: spleen and pLNs, p<0.005). In line with these results, antagonist anti-LIGHT monoclonal antibody 10F12 significantly mitigated host anti-donor cytotoxic responses against BALB/c target cells (spleen, p<0.005 and pLNs, p<0.05), and showed a trend towards protection of F1 targets that however did not reach statistical significance ( Figure  5A and 5B).
As the cytolytic response was diminished in LIGHT KO mice and also to a certain extent in anti-LIGHT-treated WT mice, we evaluated whether donor alloreactive T cell proliferation would be altered in semiallogeneic F1 recipients. Donor LIGHT KO CD4 and CD8 T cells proliferated significantly less efficiently than isotype control or anti-LIGHT treated donor WT T cells in the spleen of adoptively transferred F1 recipients ( Figure 5C ). Moreover, this observation correlated with a diminished frequency of LIGHT KO donor alloreactive CD4 T cells and CD8 T cells ( Figure 5D ) expressing IL-2Rα when compared to isotype-or anti-LIGHT treated WT donor T cells adoptively transferred into semiallogeneic F1 recipients.
Therefore, this short-term in vivo cytotoxic assay reveals that in vivo administration of anti-LIGHT mAb ameliorated the host anti-donor short-term cytotoxic response in WT B6 mice although to a lesser extent than that observed in LIGHT-deficient mice.
Discussion
The development of biologics aimed at preventing receptor / ligand interactions between TNF/TNFR molecules are alternative therapeutic arms of interest to conventional immunosuppression for the control of alloreactivity (14), (36) . One of such therapeutic targets is the process of T cell activation and differentiation that drives the acquisition of effector T cell function. The molecules involved in the exchange of information between DC/T, B/T and T/T cell interactions belong to two major families of proteins, the Immunoglobulin (Ig) superfamily and the Tumor Necrosis Factor / Tumor Necrosis Family Receptor Superfamily (TNF/TNFRSF), the latter exhibiting cysteine-rich domains in the extracellular region of the molecule (31, 37) .
In this work, we provide for the first time a monoclonal antibody capable to detect LIGHT expression on mouse T cells and NK cells, and that additionally blocks the receptor binding site of LIGHT. We also demonstrated that therapeutic intervention with this antagonist anti-LIGHT antibody protected to some extent against rejection, although it did not fully recapitulate the attenuated cytotoxic immune response seen in LIGHT-deficient mice. Although numerous reports in mouse models of inflammatory diseases have provided indirect experimental evidence that LIGHT may be involved in the pathogenesis of these immune-related diseases (10, (38) (39) (40) (41) (42) , this information contrasts with the lack of appropriate reagents for the detection of endogenous mouse LIGHT. The reason for this gap was the difficulty to engineer a genetic construct that produced a bioactive mouse LIGHT molecule with binding affinity for membrane-bound LIGHT receptors. We and others have evaluated a classical approach of fusing the extracellular region of mouse LIGHT either to Flag, the Fc fragment of the immunoglobulin heavy chain, or to an isoleucine zipper for the multimerization of the molecule (32), but none of these engineered genetic constructs succeeded in generating a protein with detectable binding affinity for mouse HVEM and LTβR. This was possible through a strategy that consisted of fusing the extracellular region of mouse LIGHT to a Flag-Foldon tag at the C-terminal site of this type II transmembrane protein (7).
Human LIGHT is constitutively expressed on intestinal mucosal CD8 T cells, CD4 T cells and NK cells and this expression is inducible by CD2-mediated signaling, which correlates with the typical activated state of resident lymphoid cells populating the intestinal mucosa (43), (44) . In contrast to mucosal sites, in peripheral blood, LIGHT is inducible after exposure to PMA/ionomycin in CD8 T cells and to a similar extent in CD4 + /CD45RO memory T cells and in CD4 Th1 IFN-γ producer cells and this expression was higher than that detected on naive CD4 T cells (44) . The differential expression of LIGHT in humans, which is constitutive on lymphocytes of mucosal tissues and inducible on peripheral blood lymphocytes, indicates that regulation of LIGHT expression is associated with an activation and responsive status of the lymphoid cell. These results are in agreement with the observed transient expression of LIGHT on mouse peripheral lymphoid cells upon exposure to PMA/ Ionomycin for 5 hours, indicating a similar regulation of inducible expression on peripheral blood of both human and mouse. This suggests that mice models of disease may contribute to unravel the physiology of LIGHT and its role during the course and in the context of an allogeneic response.
LIGHT (TNFSF14) and CD40L (also named CD154, TNFSF5) are both members of the TNF ligand superfamily. CD40L expression is not detectable on naive T cells (45) and the same holds true for the expression of human LIGHT (29) , which is agreement with the observation in our work that LIGHT expression is neither detectable on naïve T cells and NK cells and was only seen transiently upon T cell activation with a strong polyclonal stimulus. As a matter of fact, mouse LIGHT protein detection needed the presence of the fluorescently-conjugated antibody against LIGHT during in vitro stimulation of T cells and NK cells. This is probably due to the fact that LIGHT is rapidly internalized after transient surface exposure. Contrary to CD40L, which is mainly expressed on CD4 T cells, mouse LIGHT presents a more pronounced expression on CD8 T cells than on CD4 T cells, suggesting a more predominant functional role on this T cell subset.
help for CD8 T cell clonal expansion and differentiation to effector CD8 T cells. In vitro studies with LIGHT KO CD4 T cells evidenced a deficiency in IL-2 secretion compared to WT CD4 T cells in response to polyclonal activation with anti-CD3/CD28 (11), which was also noticeable in the mixed lymphocyte reaction (12) . The lack of secreted IL-2 likely contributes to the impaired CD8 T cell proliferation and differentiation to effector T cells, which also express less CD25 and therefore would proliferate less efficiently in response to IL-2 (12), (11) . In agreement with this defective in vitro functional activity, our data also reflected similar defects in vivo such as a lower frequency of donor alloreactive CD4 and CD8 T cells expressing the IL-2Rα chain and decreased proliferative rate observed in F1 recipients receiving LIGHT KO semiallogeneic splenocytes compared to F1 recipients receiving semiallogeneic B6 WT splenocytes either treated with isotype control or with anti-LIGHT mAb.
The treatment of mice with soluble decoy receptors administered as recombinant fusion proteins disrupts various ligand/receptor interactions simultaneously. Despite the indirect evidences collected from the use of these decoy receptors on different mouse models of allogeneic transplantation, these approaches do not provide clear evidence on whether LIGHT could be a potential target for immune intervention. For example, the administration of decoy receptors, such as HVEM-Ig, LTβR-Ig or sDcR3-Ig attenuates alloreactivity in murine models of disease, but it is difficult to conclude whether the observed outcome is the result of inhibiting LIGHT interaction with its receptors and to which extent the observed effects might be due in part to inhibition of other ligands such as lymphotoxin or FasL (4, (46) (47) (48) . Therefore, assignment of the most significant ligand/receptor pathway responsible for the observed in vivo effect is inherently difficult. Another consideration is that most of the decoy receptors used in preclinical rodent models of transplantation are composed of the extracellular region of the receptor bound to human IgG1 Fc fragment. It is well known that human IgG1 binds efficiently to mouse FcγRIV, the main receptor in mice involved in ADCC-mediated depletion by myeloid cells and NK cells (49) . This means that many claims in the literature stating that these decoy receptors function as blocking reagents can be biased if depletion of ligand-expressing cells indeed may occur.
In contrast to recombinant fusion proteins, selective antibody-based approaches targeting one particular ligand/receptor interaction will likely provide more relevant information than the use of soluble decoy receptors. The selective antibody-mediated blockade of the LIGHT/ HVEM/LTβR pathway prevented the in vivo host anti-donor cytotoxic alloresponse, although to a lesser extent than that seen in LIGHT-deficient mice. The relative lack of efficacy of the antibody in vivo was unexpected given the stoichiometric inhibition of LIGHT by the antibody in vitro and the favorable antibody to ligand ratio that can be achieved in vivo. Perhaps recombinant and over-expressed proteins used in vitro underestimated the binding affinity of LIGHT for its receptors in vivo, and 10F12 only partially blocked endogenous LIGHT. In this case, we predict that residual signaling may be preferentially delivered through LTβR, for which LIGHT has a higher affinity. Alternatively, LIGHT may engage its receptors in vivo in the immunological synapses established between cells that may exclude extracellular medium containing the antibody. Finally, it is also conceivable that, because of a life-long deficiency of LIGHT, LIGHT-ko mice are intrinsically hyporesponsive, a phenotype that could not be reproduced by an acute, even full inhibition of LIGHT. Although LIGHT deficiency has been associated with impaired lymphocyte migration to lymph nodes, this only occurred under strong inflammatory conditions, which are not present in our experimental in vivo cytotoxic setting. This rules out the possibility that the observed reduction of cytotoxicity in LIGHT deficient mice or anti-LIGHT treated mice was a consequence of reduced migration of the target cells to these secondary lymphoid organs (50) .
In summary, we report for the first time specific blocking and non-blocking monoclonal antibodies against mouse LIGHT as new reagents in the field of TNF/TNFR interactions to follow LIGHT protein expression and explore the preclinical consequences of interrupting LIGHT interactions with its receptors. We also demonstrated that targeting LIGHT may offer novel avenues for the control of cytotoxic responses in the setting of transplantation.
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Refer to Web version on PubMed Central for supplementary material. group. Bars indicate mean ± SEM and t test was used to compare differences between groups. 70×10 6 splenocytes from B6 WT or LIGHT-deficient mice labeled with 5 μM CFSE were injected into F1 recipients, which were treated with isotype control or anti-LIGHT 10F12 mAb. Three days later, the ratio of absolute number of donor CFSE labeled non-divided/ divided CD4 and CD8 T cells (C) as well as the absolute number of donor CD4 and CD8 T cells expressing CD25 was calculated (D). Statistical significance is indicated as follows: *, p< 0.05; **, p< 0.005; ***, p< 0.0005 and ns, non-significant. 
